{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:54:56Z","timestamp":1792007696827,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"am","delay-in-days":406,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R21AG061549"],"award-info":[{"award-number":["R21AG061549"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020141","name":"Akebia Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jacl.2022.06.011","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T06:14:07Z","timestamp":1663827247000},"page":"850-862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy"],"prefix":"10.1016","volume":"16","author":[{"given":"Marissa","family":"Lightbourne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Startzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley D.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Brite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranganath","family":"Muniyappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Skarulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shamburek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-9757","authenticated-orcid":false,"given":"Ronald","family":"Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-7382","authenticated-orcid":false,"given":"Rebecca J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2022.06.011_bib0001","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.06.011_bib0002","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ecl.2017.01.012","article-title":"Genetics of Lipodystrophy","volume":"46","author":"Lightbourne","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jacl.2022.06.011_bib0003","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.06.011_bib0004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4158\/EP09154.RA","article-title":"Clinical classification and treatment of congenital and acquired lipodystrophy","volume":"16","author":"Chan","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2022.06.011_bib0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0002-9343(02)01070-7","article-title":"Multisystem dystrophy syndrome due to novel missense mutations in the amino-terminal head and alpha-helical rod domains of the lamin A\/C gene","volume":"112","author":"Garg","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0006","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.06.011_bib0007","unstructured":"Agency EM. Myalepta Vol 2021. European Medicines Agency Science Medicines Health Website: European Medicines Agency Science Medicines Health 2018."},{"key":"10.1016\/j.jacl.2022.06.011_bib0008","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacl.2022.06.011_bib0009","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1742-1241.2007.01678.x","article-title":"An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?","volume":"62","author":"Chan","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2022.06.011_bib0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/07853890310011969","article-title":"Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients","volume":"35","author":"Lemieux","year":"2003","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0011","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2022.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1056\/NEJMoa0907295","article-title":"Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease","volume":"362","author":"Petersen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0014","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jacl.2022.06.011_bib0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0016","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0017","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.06.011_bib0018","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2022.06.011_bib0019","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1210\/jc.2015-3891","article-title":"Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy","volume":"101","author":"Kassai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2022.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jacl.2022.06.011_bib0021","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2022.06.011_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Analytical biochemistry"},{"key":"10.1016\/j.jacl.2022.06.011_bib0023","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2022.06.011_bib0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1148\/radiol.12112344","article-title":"Liver metabolite concentrations measured with 1H MR spectroscopy","volume":"265","author":"Ouwerkerk","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jacl.2022.06.011_bib0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2337\/diacare.26.3.557","article-title":"Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults","volume":"26","author":"Duncan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2022.06.011_bib0026","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0014-5793(76)80145-7","article-title":"Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase","volume":"65","author":"Kinnunen","year":"1976","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jacl.2022.06.011_bib0027","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","article-title":"Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins","volume":"30","author":"Mendivil","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.06.011_bib0028","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCRESAHA.110.219188","article-title":"Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins","volume":"107","author":"Brown","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2022.06.011_bib0029","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.2167514","article-title":"Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice","volume":"249","author":"Ito","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jacl.2022.06.011_bib0030","doi-asserted-by":"crossref","first-page":"31348","DOI":"10.1074\/jbc.272.50.31348","article-title":"Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor","volume":"272","author":"Mann","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2022.06.011_bib0031","doi-asserted-by":"crossref","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","article-title":"Apolipoprotein CIII links islet insulin resistance to beta-cell failure in diabetes","volume":"112","author":"Avall","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2022.06.011_bib0032","unstructured":"Akcea Therapeutics I. Akcea and Ionis report top-line results from the BROADEN Study with WAYLIVRA\u00ae (volanesorsen) in patients with familial partial lipodystrophy 2019."},{"key":"10.1016\/j.jacl.2022.06.011_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2022.08.008","article-title":"Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study: Volanesorsen in FPLD; The BROADEN Study","author":"Oral","year":"2022","journal-title":"J. Clin. Lipidol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:37:57Z","timestamp":1761831477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1933287422002495"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.06.011","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}